NCT01892839

Brief Summary

Hemodialysis keeps patients with renal failure alive but does not restore normal health. Retention of chemicals that bind to plasma proteins and are therefore poorly removed by dialysis may contribute to ill health in patients receiving conventional treatment. This proposal will test the effect of a new method designed to improve the removal of protein-bound solutes during dialysis. The effects on blood chemical levels of two different dialysis prescriptions will be tested in patients already undergoing nocturnal in-center hemodialysis three times weekly.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 27, 2013

Completed
4 days until next milestone

Study Start

First participant enrolled

July 1, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 4, 2013

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

July 13, 2015

Status Verified

July 1, 2015

Enrollment Period

2.4 years

First QC Date

June 27, 2013

Last Update Submit

July 9, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Plasma levels of the chemical p-cresol sulfate

    Participants will be followed for 2-3 weeks on different dialysis prescriptions and plasma chemical levels will be measured at the end of this period.

Study Arms (2)

high dialysate flow, larger dialyzer

EXPERIMENTAL

high dialysate flow, larger dialyzer

Other: high dialysate flow, larger dialyzer

low dialysate flow, smaller dialyzer

ACTIVE COMPARATOR

low dialysate flow, smaller dialyzer

Other: low dialysate flow, smaller dialyzer

Interventions

The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.

low dialysate flow, smaller dialyzer

The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.

high dialysate flow, larger dialyzer

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • stable on nocturnal in-center dialysis located close to Stanford University and VA Palo Alto

You may not qualify if:

  • recent use of antibiotics
  • gastrointestinal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Satellite Redwood City

Redwood City, California, 94063, United States

RECRUITING

Stanford University

Stanford, California, 94301, United States

RECRUITING

Study Officials

  • Timothy W Meyer, MD

    PAIRE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

tim meyer, md

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2013

First Posted

July 4, 2013

Study Start

July 1, 2013

Primary Completion

December 1, 2015

Study Completion

December 1, 2016

Last Updated

July 13, 2015

Record last verified: 2015-07

Locations